NKTR.NASDAQNektar Therapeutics
SCHEDULE: BlackRock Discloses 1.6% Passive Stake in Nektar Therapeutics
Sentiment:
Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 1.6% of Nektar Therapeutics' common stock as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 203,017 shares of Nektar Therapeutics' common stock.
- This ownership represents 1.6% of the total class of securities.
- BlackRock holds sole voting power over 201,953 shares and sole dispositive power over 203,017 shares.
- The filing is an Amendment No. 2 to a Schedule 13G, indicating a passive investment strategy.
- BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Nektar Therapeutics.
- The filing identifies several BlackRock subsidiaries as relevant, including BlackRock (Netherlands) B.V., BlackRock Advisors, LLC, BlackRock Financial Management, Inc., BlackRock Fund Advisors, BlackRock Institutional Trust Company, National Association, and BlackRock Investment Management, LLC.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of passive ownership, providing factual information without indicating positive or negative sentiment regarding the issuer's performance or prospects.
Positives
- BlackRock's passive investment indicates a standard portfolio holding rather than an activist stance, which can be seen as a stable, non-disruptive presence for Nektar Therapeutics.
- The filing confirms BlackRock's continued, albeit small, interest in Nektar Therapeutics' common stock.
Negatives
- The filing itself does not present any negative aspects regarding Nektar Therapeutics' operations or financial health, as it is purely an ownership disclosure.
Risks
- The document does not detail specific risks related to Nektar Therapeutics' business operations or financial performance.
- BlackRock's certification explicitly states that their holdings are not for the purpose of influencing control, which mitigates the risk of activist pressure from this specific shareholder.
Management Comments
- Securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Attorney-in-Fact | Previous attorneys-in-fact under the April 30, 2023 power of attorney | Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David Rothenberg, Brenda Schulz | 2025-01-21 | New power of attorney issued, expressly revoking the prior one, to appoint new or reconfirm existing attorneys-in-fact for regulatory filings. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. issued a new Power of Attorney, effective January 21, 2025, appointing several individuals as attorneys-in-fact for executing SEC and other regulatory filings, expressly revoking the prior Power of Attorney dated April 30, 2023. | 2025-01-21 | Streamlines BlackRock's internal process for compliance with ownership and control-person reporting requirements across its various business units and affiliates. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake in Nektar Therapeutics, confirming that BlackRock is not seeking to influence control.
- Regulatory Authorities: Fulfills SEC disclosure requirements for beneficial ownership, ensuring compliance with reporting obligations.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of the previous Power of Attorney for BlackRock, Inc., which was expressly revoked by the new one. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc., appointing attorneys-in-fact for SEC filings. |
| 2025-06-30 | Date of event which required the filing of this Schedule 13G statement. |
| 2025-07-18 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Keywords
Nektar Therapeutics, BlackRock, Schedule 13G, Common Stock, Beneficial Ownership, SEC Filing, Institutional Investor, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.